Weight Loss Surgery Increases Kidney Transplant Rates in Patients With Renal Failure and Obesity

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F24%3A10480004" target="_blank" >RIV/00179906:_____/24:10480004 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/24:10480004

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=bQdm_o94Z9" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=bQdm_o94Z9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.mayocp.2024.01.017" target="_blank" >10.1016/j.mayocp.2024.01.017</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Weight Loss Surgery Increases Kidney Transplant Rates in Patients With Renal Failure and Obesity

Popis výsledku v původním jazyce

Objective: To describe the outcomes of kidney transplant (KT) candidates with obesity undergoing sleeve gastrectomy (SG) to meet the criteria for KT.Methods: Retrospective analysis was conducted of electronic medical records of KT candidates with obesity (body mass index &gt;35 kg/m2) who underwent SG in our institution. Weight loss, adverse health events, and the listing and transplant rates were abstracted and compared with the nonsurgical cohort.Results: The SG was performed in 54 patients; 50 patients did not have surgery. Baseline demographic characteristics were comparable at the time of evaluation. Mean body mass index SD of the SG group was 41.73.6 kg/m2 at baseline (vs 41.54.3 kg/m2 for nonsurgical controls); at 2 and12 months after SG, it was 36.44.1 kg/m2 and 32.64.0 kg/m2 (P&lt;.01 for both). In the median follow-up time of 15.5 months (interquartile range, 6.4 to 23.9 months), SG was followed by activelisting (37/54 people), and 20 of 54 received KT during a median follow-up time of 20.9 months (interquartile range, 14.7 to 28.3 months) after SG. In contrast, 14 of 50 patients in the nonsurgical cohort were listed, and 5 received a KT (P&lt;.01). Three patients (5.6%) experienced surgical complications. There was no difference in overall hospitalization rates and adverse health outcomes, but the SG cohort experienced a higher risk of clinically significant functional decline.Conclusion: In KT candidates with obesity, SG appears to be effective, with 37% of patients undergoing KT during the next 18 months (P&lt;.01). Further research is needed to confirm and to improve the safety and efficacy of SG for patients with obesity seeking a KT.

Název v anglickém jazyce

Weight Loss Surgery Increases Kidney Transplant Rates in Patients With Renal Failure and Obesity

Popis výsledku anglicky

Objective: To describe the outcomes of kidney transplant (KT) candidates with obesity undergoing sleeve gastrectomy (SG) to meet the criteria for KT.Methods: Retrospective analysis was conducted of electronic medical records of KT candidates with obesity (body mass index &gt;35 kg/m2) who underwent SG in our institution. Weight loss, adverse health events, and the listing and transplant rates were abstracted and compared with the nonsurgical cohort.Results: The SG was performed in 54 patients; 50 patients did not have surgery. Baseline demographic characteristics were comparable at the time of evaluation. Mean body mass index SD of the SG group was 41.73.6 kg/m2 at baseline (vs 41.54.3 kg/m2 for nonsurgical controls); at 2 and12 months after SG, it was 36.44.1 kg/m2 and 32.64.0 kg/m2 (P&lt;.01 for both). In the median follow-up time of 15.5 months (interquartile range, 6.4 to 23.9 months), SG was followed by activelisting (37/54 people), and 20 of 54 received KT during a median follow-up time of 20.9 months (interquartile range, 14.7 to 28.3 months) after SG. In contrast, 14 of 50 patients in the nonsurgical cohort were listed, and 5 received a KT (P&lt;.01). Three patients (5.6%) experienced surgical complications. There was no difference in overall hospitalization rates and adverse health outcomes, but the SG cohort experienced a higher risk of clinically significant functional decline.Conclusion: In KT candidates with obesity, SG appears to be effective, with 37% of patients undergoing KT during the next 18 months (P&lt;.01). Further research is needed to confirm and to improve the safety and efficacy of SG for patients with obesity seeking a KT.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Mayo Clinic Proceedings

ISSN

0025-6196

e-ISSN

1942-5546

Svazek periodika

99

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

705-715

Kód UT WoS článku

001240052400001

EID výsledku v databázi Scopus

2-s2.0-85191182142